Form 4: Arcellx Director Executes Stock Option and Sells Shares Under 10b5-1 Plan

Arcellx director Kavita Patel exercised stock options and sold shares on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On November 12, 2024, Arcellx director Kavita Patel exercised stock options to acquire 1,500 shares of common stock at a price of $6.66 per share.
• Concurrently, Ms. Patel sold 1,500 shares of common stock at a price of $106.33 per share.
• The sale was executed under a Rule 10b5-1 trading plan established on March 28, 2024.
• Following these transactions, Ms. Patel holds 42,077 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine filing of insider trading activity. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who trade their company's stock. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate insiders at publicly traded companies like Arcellx, including companies such as Amgen, Gilead, and Regeneron.
• The vesting schedule of the stock options, with 25% vesting after one year and the remainder monthly, is a typical structure for equity grants in the biotech industry, similar to those used by companies like Moderna and BioNTech.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement for all publicly traded companies in the US.

Stakeholder Impact

• The transactions have a minimal impact on stakeholders as they are part of a pre-arranged trading plan.

Key Dates

Keywords

Arcellx, stock options, insider trading, Form 4, Rule 10b5-1, equity incentive plan, director, Kavita Patel